InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,718.80
(
0.44%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.28
(
0.39%
)
Bitcoin
62,998.50
(
-0.08%
)
Post# of 13897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

the_hoard

Send PM Follow Ignore
Followers 3
Posts 336
Boards Moderated 0
Alias Born 03/25/2019

the_hoard

Re: trader59 post# 11886

Wednesday, 12/08/2021 3:32:10 PM

Wednesday, December 08, 2021 3:32:10 PM

Post# of 13897
Note the date: Mar 16, 21

https://scrip.pharmaintelligence.informa.com/deals/201720309

Cytovia Inc., the oncology division of Immune Pharmaceuticals Inc., granted Pint Pharma GMBH rights to market and distribute Ceplene (histamine dihydrochloride) for acute myeloid leukemia in Latin America, including Argentina, Brazil, Chile, Colombia, and Mexico.

Dr. Hellstrand of Cytovia Therapeutics has been doing research on Ceplene. It’s even on the companies official Twitter. Seems like there is a connection. Immune licensed months after Ceplene was assigned to Discover in bankruptcy.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up